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Abstract It has been known that there is a relationship be-
tween cannabis use and schizophrenia-related symptoms;
however, it can be a subject of controversy. The involvement
of CB1 receptor ligands in the schizophrenia has already been
revealed and confirmed. However, there is still lack of infor-
mation concerning the role of CB2 receptors in the psychosis-
like effects in mice and the further studies are needed.
The aim of the present research was to study the role of the
CB2 receptor ligands in the symptoms typical for schizophre-
nia. We provoked hyperlocomotion in mice which is analo-
gous to positive psychosis-like effects in humans, by an acute
administration of a NMDA receptor antagonist, MK-801 (0.3
and 0.6 mg/kg), a pharmacological model of schizophrenia.
An acute administration of MK-801 induced the increase in
locomotor activity (hyperactivity) in rodents, measured in
actimeters.
We revealed that an acute injection of CB2 receptor agonist
JWH 133 at the dose range (0.05–1.0 mg/kg) and CB2 recep-
tor antagonist, AM 630 at the dose range (0.1–1.0 mg/kg)
decreased locomotion of mice. An acute injection of JWH
133 (2.0 mg/kg) and AM 630 (2.0 mg/kg) had no statistical
significant influence on the locomotor activity of mice.
However, an acute injection of both CB2 receptor ligands
(agonist and antagonist), JWH 133, at the non-effective dose
of 2.0 mg/kg and AM 630 at the non-effective dose of
2.0 mg/kg, potentiated the MK-801-induced hyperactivity.
The present findings have confirmed that endocannabinoid
system, not only via CB1, but also via CB2 receptors, may be
involved in the schizophrenia-like responses, including
hyperlocomotion in mice.
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Abbreviations
Δ9-THC-Δ9 Tetrahydrocannabinol
CB1 Cannabinoid receptor of type 1
CB2 Cannabinoid receptor of type 2
(CB1−/−) CB1 receptor knockout mice
(CB2−/−) CB2 receptor knockout mice
CB Cannabinoid
CBD Cannabidiol
CNS Central nervous system
GABA ɣ-Amino-butyric acid
ip Intraperitoneally




VTA Ventral tegmental area
Introduction
Schizophrenia is a chronic mental disorder that combines
a variety of clinical symptoms, including positive (e.g.,
hallucinations, psychosis), negative (e.g., amotivation, an-
hedonia), and cognitive (e.g., deficits in attention and
memory) symptoms (Lewis and Lieberman, 2000). As
yet, the etiology of schizophrenia remains unclear.
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Experts support that schizophrenia is caused by several
factors, including gene- and environment-related factors,
as well as by an imbalance in the function of many
neurotransmitters systems, e.g., dopaminergic, gluta-
matergic, gamma-aminobutyric(GABA)-related system,
endocannabinoid system, and possibly others (Broome
et al. 2005; Carlsson et al. 2004).
The endocannabinoid system, through cannabinoid
(CB) receptors, and its interactions with a multitude of
neurotransmitters and receptors, is involved in many
physiological and physical functions, which correspond
with distribution of CB receptors (Grotenhermen 2004).
Currently, two types of CB receptors are known: CB1 and
CB2. CB1 receptors are widely distributed in the central
nervous system (CNS), especially in the limbic system
and on the brain areas related to emotional responses,
including basal ganglia, amygdala, cerebellum, hippocam-
pus, and prefrontal cortex. In turn, CB2 receptors are
mostly located in cells of the immune system and can be
also found on the brain areas, such as cerebellum and
hippocampus and in microglia (Svízenská et al. 2008).
Due to localization of CB (CB1 as well CB2) receptors,
endocannabinoid system is able to modulate many
cognitive- and emotional-related responses in the CNS,
e.g., stress, anxiety, mood, and aggressive behavior.
Thus, this system plays an important role in the pathology
of many CNS-related disorders, such as depression, mem-
ory loss, and schizophrenia (Grotenhermen 2004).
Recently, many literature data support that changes in
the endocannabinoid system in the brain may be in-
volved in the pathology of schizophrenia, and this sys-
tem is impaired in schizophrenia. Furthermore, there is
emerging evidence to support a number of associations
between cannabis and psychosis. Several lines of exper-
imental and clinical evidence point to a close relationship
between endocannabinoid system and schizophrenia as
cannabis use may precipitate or exacerbate the symptoms
of this disease. Some studies have indicated that expo-
sure to cannabis is associated with cognitive impairment
and increased risk of developing psychosis (Arseneault
et al. 2004; Moore et al. 2007). Additionally, there is
evidence that the brains of people with psychosis who
previously used cannabis differ significantly from those
of healthy individuals (Rapp et al. 2012). Moreover, it
has been revealed that people with psychosis have higher
rates of cannabis use, and that there exists an association
between cannabis use and schizophrenia, and other re-
search has consistently found that cannabis use is asso-
ciated with an earlier age at onset of schizophrenia
(Large et al. 2011).
This relationship has been confirmed in behavioral exper-
iments (Liu et al. 2009; Marsicano et al. 2003). A variety of
animal studies found a dysregulation of endocannabinoid
signaling in psychosis. For example, in animal models, it
has been demonstrated that CB1 receptor agonists often in-
duced cognitive impairments in rodents (Ferrari et al. 1999;
Kruk-Slomka and Biala 2016; Pamplona and Takahashi 2006)
and induced psychosis-like symptoms (Levin et al. 2012;
Roser and Haussleiter, 2012). However, it is still not clear
whether and why the use of cannabis causes or exacerbates
psychosis.
On the other hand, due to their properties, cannabinoids
appear to be a promising therapeutic target in the treatment of
many diseases, such as psychosis-like symptoms. It has been
revealed that antagonism of CB1 receptors generally enhanced
rodent performance in variety memory tasks (Kruk-Slomka
and Biala 2016; Kruk-Slomka et al. 2016a; Kruk-Slomka
et al. 2016b; Lichtman 2000; Takahashi et al. 2005;
Terranova et al. 1996), as well as had antipsychotic properties
evaluated in animal models of schizophrenia (Almeida et al.
2014; Kruk-Slomka et al. 2016b; Levin et al. 2012; Roser and
Haussleiter 2012; Radhakrishnan et al. 2014).
Since then, a number of studies have investigated the
association between cannabis and psychosis. Although,
the involvement of CB1 receptor ligands in the schizo-
phrenia has already been revealed and confirmed (Kruk-
Slomka et al. 2016b), there is still lack of clear evidence
regarding the central mechanisms of action and effects of
CB2 receptor ligands, especially the role of CB2 receptors
in the processes connected with the psychosis-like symp-
toms. There is only a few literature data indicating a pos-
sible role of CB2 receptors in schizophrenia-related re-
sponses (Ishiguro et al. 2010; Khella et al. 2014;
Ortega-Alvaro et al. 2011). Therefore, continuing in the
line of our earlier studies (Kruk-Slomka et al. 2016b), in
which we revealed and confirmed that CB1 receptor an-
tagonist is able to attenuate the MK-801-induced
hyperlocomotion, the aim of presented studies was to de-
termine the potential antipsychotic status of CB2 receptor
ligands and their influence on the hyperactivity in mice in
this pharmacological model. We used CB2 receptor ago-
nist, JWH 133 and CB2 receptor antagonist, AM 630.
Alike the previous experiments (Kruk-Slomka et al.
2016b), we induced an increased locomotion in mice by
an acute administration of N-methyl-D-aspartate (NMDA)
receptor antagonist, MK-801, which is often used to pre-
dict the effect of many compounds with potential antipsy-
chotic properties (Kovacic and Somanathan 2010).
The results obtained from these experiments will help to
confirm the role for CB2 receptor subtype in the modulation
of behaviors associated with an animal model of
hyperlocomotion and schizophrenia. Following that, our re-
sults can also help to increase knowledge concerning the re-
lationship between cannabis use and psychosis, focusing on
the CB2 receptors, and to explain precise nature of these as-
sociations more clearly.
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Materials and Methods
Animals
Male Swiss mice (Farm of Laboratory Animals, Warszawa,
Poland) weighting 20–30 g were housed under laboratory
conditions of controlled temperature (21 ± 1 °C), lighting
(12/12 h light/dark cycle) with food (Agropol, Motycz,
Poland) and tap water available ad libitum. Animals were
habituated to housing conditions for 1 week and behavioral
testing was carried out during the light cycle (between 8:00
and 15:00).
Mice were used only once and were drug-naive before each
experiment. Experiments were performed in accordance with
the National Institute of Health Guidelines for the Care and
Use of Laboratory Animals and the European Community
Council Directive for the Care and Use of laboratory animals
of 22 September 2010 (2010/63/EU), and approved by the
local ethics committee.
Drugs
The following drugs were used:
1. JWH 133 (0.05, 0.1, 0.25, 0.5, 1.0, 2.0 mg/kg) (Tocris,
USA)—CB2 receptor agonist
2. AM 630 (0.1, 0.25, 0.5, 1.0, 2.0 mg/kg) (Tocris, USA)—
CB2 receptor antagonist
3. MK-801 (0.3, 0.6 mg/kg) (Tocris, USA)—NMDA receptor
antagonist
CB2 receptor ligands and MK-801 were suspended in the
1% solution of polyoxyethylenesorbitan monooleate (Tween
80) (Sigma, St. Louis, MO, USA) and then diluted in a 0.9%
saline solution (NaCl). All solutions were injected intraperito-
neally (ip) at a volume of 10 ml/kg body weight. Saline plus
Tween 80 was used as a control solution (vehicle), at the same
volume and by the same route of administration. Fresh drug
solutions were prepared on each day of experimentation.
Experimental doses of drugs used and procedures were
selected on the basis of literature data (Bubenikova-Valesova
et al. 2010; Kovacic and Somanathan 2010; Nestler and
Hyman 2010; Mohn et al. 1999; Zhou et al. 2012), our previ-
ous experiments (Kruk-Slomka et al. 2015; Kruk-Slomka and
Biala 2016; Kruk-Slomka et al. 2016a; Kruk-Slomka et al.
2016b), and preliminary studies. The doses ofMK-801 as well
as the scheme of treatment was based on our previous exper-
iments (Kruk-Slomka et al. 2016b).
Experimental Procedures
Schizophrenia-like behavior was assessed using the common-
ly accepted pharmacological animal model of schizophrenia
based on psychotic properties of MK-801. Mice were acutely
injected with MK-801 inducing hyperlocomotion which cor-
relates with the psychomotor agitation seen in schizophrenia
patients (Bubenikova-Valesova et al. 2010; Nestler and
Hyman 2010).
Firstly, the influence of CB2 receptor ligands, JWH 133
and AM 630, on the locomotor activity of mice was investi-
gated and then the impact of JWH 133 and AM 630 on the
hyperactivity provoked by MK-801 was estimated.
Locomotion of mice was measured in actimeters.
Locomotion
Locomotion of mice was recorded individually in round
actometer cages (Multiserv, Lublin, Poland; 32 cm in diame-
ter, two light beams) kept in a sound-attenuated experimental
room. Two photocell beams, located across the axis, automat-
ically measured animal’s movements. The horizontal locomo-
tor activity, i.e., the number of photocell beam breaks, was
automatically measured with a 20-min interval for 200 min
(Mohn et al. 1999; Zhou et al. 2012).
Treatment
For Psychotic-like Symptoms
Horizontal locomotor activity was measured immediately af-
ter an acute injection of JWH 133 (0.05, 0.1, 0.25, 0.5, 1.0,
2.0 mg/kg, ip), AM 630 (0.1, 0.25, 0.5, 1.0, 2.0 mg/kg, ip), or
vehicle for the control group. Next, we evaluated the impact of
an acute administration of JWH 133 (2.0 mg/kg, ip) or AM
630 (2.0 mg/kg, ip) on the hyperlocomotion of mice provoked
by an acute MK-801 (0.3 and 0.6 mg/kg, ip). For this purpose,
JWH 133, AM 630, or vehicle were administered 15 min be-
fore injection of MK-801 or vehicle. The mice were then
tested immediately after the last injection.
Statistical Analysis
The statistical analysis were performed using two-way
ANOVA—for the factors of time, drug treatment (JWH 133,
AM 630, and/or MK-801), and time/drug treatment interac-
tions for the locomotor effects.
Post hoc comparison of means was carried out with the
Bonferroni’s test for multiple comparisons, when appropriate.
The data were considered statistically significant at confidence
limit of p < 0.05. ANOVA analysis with Bonferroni’s post
tests were performed using GraphPad Prism version 5.00 for
Windows, GraphPad Software, San Diego California USA,
www.graphpad.com.
For the psychotic-like symptoms, the horizontal loco-
motor activity, i.e., the number of photocell beam breaks,
was measured.
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Results
First, we evaluated the influence of CB2 receptor ligands (ag-
onist and antagonist) on the locomotion of mice in actimeters.
An acute injection of JWH 133, CB2 receptor agonist de-
creased locomotion of mice at the dose range 0.05–1.0 mg/kg.
Similarly, an acute injection of AM 630. CB2 receptor antago-
nist, decreased locomotion of mice at the dose range 0.1–
1.0 mg/kg. In turn, an acute injection of both JWH 133 at the
dose of 2.0 and AM 630 at the dose of 2.0 had no influence on
the locomotion of mice. Therefore, these non-effective doses
of JWH 133 and AM 630 (2.0 mg/kg) have been chosen to
the next experiments dealing MK-801.
The Influence of CB2 Receptor Agonist, JWH 133,
on the Locomotor Activity of Mice
Two-way ANOVA analyses revealed that there was statistical-
ly significant effect caused by time [F(10,418) = 44.04,
p < 0.0001] and JWH 133 treatment [F(6418) = 16.30,
p < 0.0001], but there was no statistically significant effect
caused by interactions between time and JWH 133 treatment
[F(60,418) = 0.94, p = 0.6122]. The Bonferroni’s test revealed
that an acute injection of JWH 133, at the dose range (0.05–
1.0 mg/kg), significantly decreased locomotion in mice in
comparison to the vehicle-treated control group between the
following minutes of the experiment as follows:
1. Between 140 and 200 min of experiment for the dose of
0.05 mg/kg of JWH 133: 140 min (p < 0.05), 160 min
(p < 0.01), and 180–200 min (p < 0.001)
2. Between 100 and 200 min of experiment for the dose of
0.1 mg/kg of JWH 133: 100 min (p < 0.05), 120 min
(p < 0.01), and 140–200 min (p < 0.001)
3. Between 180 and 200 min of experiment for the dose of
0.25 mg/kg of JWH 133: p < 0.01
4. Between 180 and 200 min of experiment for the dose of
0.5 mg/kg of JWH 133: 180 min (p < 0.05), 200 min
(p < 0.01)
5. Between 120 and 200 min of experiment for the dose of
1.0 mg/kg of JWH 133: 120 min (p < 0.05), 140–180 min
(p < 0.01), 200 min (p < 0.001)
JWH 133 at the dose of 2.0 mg/kg had no influence on the
locomotor activity of mice in comparison to the vehicle-
treated control group (Fig. 1).
The Influence of CB2 Receptor Antagonist, AM 630
on the Locomotor Activity of Mice
Two-way ANOVA analyses revealed that there was statistical-
ly significant effect caused by time [F(10,341) = 40.07,
p < 0.0001] and AM 630 treatment [F(5341) = 20.01,
p < 0.0001], but there was no statistically significant effect
caused by interactions between time and AM 630 treatment
[F(50,341) = 1.20, p = 0.1827]. The Bonferroni’s test revealed
that an acute injection of AM 630 at the dose range (0.1–
1.0 mg/kg) significantly decreased locomotion in mice in
comparison to the vehicle-treated control group between the
following minutes of the experiment as follows:
1. Between 140 and 200 min of experiment for the dose of
0.1 mg/kg of AM 630: 140–160 min (p < 0.05), 180 min
(p < 0.01), and 200 min (p < 0.001)
2. Between 100 and 200 min of experiment for the dose of
0.25 mg/kg of AM 630: 100 min (p < 0.05), 120 min
(p < 0.01), and 140–200 min (p < 0.001)
3. Between 120 and 200 min of experiment for the dose of
0.5 mg/kg of AM 630: 120 min (p < 0.05), 140 min
(p < 0.01), and 160–200 min (p < 0.001)
4. Between 160 and 200 min of experiment for the dose of
1.0 mg/kg of AM 630: 160 min (p < 0.05) and 180–
200 min (p < 0.01)
AM 630 at the dose of 2.0 mg/kg had no influence on the
locomotor activity of mice in comparison to the vehicle-
treated control group (Fig. 2).
Then, we induced the hyperlocomotion which mimics pos-
itive symptom characteristic for schizophrenia, by an acute
administration of MK-801, and evaluated the influence of
CB2 receptor ligands on this MK-801-related hyperactivity.
Based on our previously conducted experiments (Kruk-
Slomka et al. 2016b) as well as on the results obtained from
the experiments described above, the effective doses of MK-
801 (0.3 and 0.6 mg/kg) and non-effective dose of JWH 133
(2.0 mg/kg) and AM 630 (2.0mg/kg) were then chosen for the
next behavioral experiment evaluating the involvement of
CB2 receptors on MK-801-induced hyperactivity.
In these experiments, we revealed that an acute injection of
both CB2 receptor agonist and antagonist had influence on the
MK-801-induced hyperlocomotion of mice. The non-
effective dose of JWH 133 (2.0 mg/kg) potentiated the
hyperlocomotion of mice provoked by an acute injection of
MK-801 at the dose of 0.6 mg/kg. Similarly, an acute injection
of non-effective dose of AM 630 (2.0 mg/kg) potentiated the
hyperlocomotion of mice provoked by an acute injection
of MK-801 both at the dose of 0.3 and 0.6 mg/kg, as
described below.
The Influence of the Administration of JWH 133
on the Hyperactivity of Mice Provoked by an Acute
Administration of MK-801
Two-way ANOVA analyses revealed that there was statistical-
ly significant effect caused by time [F(10,264) = 32.84,
p < 0.0001] and drug (MK-801 (0.3 mg/kg) and/or JWH 133
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(2.0mg/kg) treatment [F(3264) = 81.27, p < 0.0001], as well as
caused by interactions between time and drug treatment
[F(30,264) = 2.73, p < 0.0001]. The post hoc Bonferroni’s test
confirmed that an acute injection of MK-801 at the dose of
0.3 mg/kg significantly increased locomotor activity of mice
between 60 and 200 min of experiment as compared with the
vehicle/vehicle-injected control group (for 60–80 min of ex-
periments p < 0.05, for 100–120 min p < 0.01, for 140 min
p < 0.001, for 160 min p < 0.01, and for 180–200 min
p < 0.001). JWH 133 (2.0 mg/kg) had no influence on MK-
801 (0.3 mg/kg)-induced hyperactivity (Fig. 3a).
For the second dose ofMK-801 used (0.6mg/kg), two-way
ANOVA analyses revealed that there was statistically signifi-
cant effect caused by time [F(10,264) = 80.87, p < 0.0001],
and drug (MK-801 (0.6 mg/kg) and/or JWH 133 (2.0 mg/kg)
treatment [F(3264) = 213.39, p < 0.0001], as well as by inter-
actions between time and drug treatment [F(30,264) = 8.72,
p < 0.0001]. The post hoc Bonferroni’s test revealed that MK-
801 at the dose of 0.6 mg/kg significantly increased locomotor
activity of mice in actimeters between 60 and 200 min of
experiment (for 60 min of experiment p < 0.01, for 80–
200 min p < 0.001), in comparison to the vehicle/vehicle-
treated mice. Moreover, this hyperactivity provoked by MK-
801 (0.6 mg/kg) was potentiated by JWH 133 (2.0 mg/kg)
between 180 and 200 min of experiment (p < 0.05 vs.
vehicle/MK-801 (0.6 mg/kg)-treated mice) (Fig. 3b).
The Influence of the Administration of AM 630
on the Hyperactivity of Mice Provoked by an Acute
Administration of MK-801
Two-way ANOVA analyses revealed that there was statisti-
cally significant effect caused by time [F(10,242) = 66.29,
p < 0.0001] and drug (MK-801 (0.3 mg/kg) and/or AM 630
(2.0 mg/kg) treatment [F(3242) = 261.74, p < 0.0001], as
well as caused by interactions between time and drug treat-
ment [F(30,242) = 8.11, p < 0.0001]. The post hoc
Bonferroni’s test confirmed that an acute injection of MK-
801 at the dose of 0.3 mg/kg significantly increased loco-
motor activity of mice between 40 and 200 min of
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Fig. 2 Effects of an acute AM
630 or vehicle administration on
the locomotor activity of mice.
AM 630 (0.1, 0.25, 0.5, 1.0, and
2.0 mg/kg; ip) or vehicle were
injected immediately before the
test; n = 8–12; the means ± SEM;
*p < 0.05; **p < 0.01;
***p < 0.001 vs. vehicle-treated
control group; Bonferroni’s test
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Fig. 1 Effects of an acute JWH
133 or vehicle administration on
the locomotor activity of mice.
JWH 133 (0.05, 0.1, 0.25, 0.5,
1.0, and 2.0 mg/kg; ip) or vehicle
were injected immediately before
the test; n = 8–12; the
means ± SEM; *p < 0.05;
**p < 0.01; ***p < 0.001 vs.
vehicle-treated control group;
Bonferroni’s test
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experiment as compared with the vehicle/vehicle-injected
control group (for 40 min of experiment p < 0.01, for 60–
200 min p < 0.001). Moreover, this hyperactivity provoked
by MK-801 (0.3 mg/kg) was potentiated by an acute injec-
tion of AM 630 (2.0 mg/kg) between 100 and 200 min of
experiment (for 100 min of experiment p < 0.05, for 120–
200 min of experiment p < 0.001 vs. vehicle/MK-801
(0.3 mg/kg)-treated mice) (Fig. 4a).
Similarly, for the second dose ofMK-801 used (0.6mg/kg),
two-wayANOVA analyses revealed that there was statistically
significant effect caused by time [F(10,242) = 67.19,
p < 0.0001] and drug (MK-801 (0.6 mg/kg) and/or AM 630
(2.0 mg/kg) treatment [F(3242) = 213.41, p < 0.0001], as well
as by interactions between time and drug treatment
[F(30,242) = 8.58, p < 0.0001. The post hoc Bonferroni’s test
revealed that MK-801 at the dose of 0.6 mg/kg significantly
increased locomotor activity of mice in actimeters between 80
and 200 min of experiment (p < 0.001), in comparison to the
vehicle/vehicle-treated mice. Moreover, this hyperactivity
provoked by MK-801 (0.6 mg/kg) was increased by AM
630 (2.0 mg/kg) between 140 and 200 min of experiment
(for 140 min of experiment p < 0.05, for 160 min p < 0.01,
for 180–200 min of experiment p < 0.001 vs. vehicle/MK-801
(0.6 mg/kg)-treated mice) (Fig. 4b).
Discussion
The aim of the present research was to determine the involve-
ment of the endocannabinoid system, through CB2 receptors,
in the hyperlocomotion of mice, provoked by an acute injec-
tion of NMDA receptor antagonist, MK-801, as an animal
pharmacological model of schizophrenia.
We revealed that an acute injection of AM 630, CB2 re-
ceptor antagonist, used in our experiments at the doses 0.1–
1.0 mg/kg, but not at the dose of 2.0 mg/kg, decreased loco-
motion of mice. An acute injection of AM 630 (2.0 mg/kg) of
its own had no statistical significant influence on the locomo-
tor activity of mice. However, in the next step, we revealed
that an acute injection of AM 630, at the non-effective dose of
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Fig. 3 Effect of JWH 133 on
MK-801-induced hyperactivity in
mice. Non-effective dose of JWH
133 (2.0 mg/kg, ip) or vehicle
were administered 15 min prior to
vehicle or effective (0.3 mg/kg,
ip) (a) and (0.6 mg/kg, ip) (b)
dose of MK-801. After the last
injection, the mice were then
tested in actimeters; n = 8–12; the
means ± SEM; *p < 0.05;
**p < 0.01; ***p < 0.001 vs.
vehicle/vehicle-treated group;
^p < 0.05 vs. vehicle/MK-
801(0.6 mg/kg)-treated group
Bonferroni’s test
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2.0 mg/kg, potentiated MK-801-induced hyperactivity. What
is of interest, we revealed that an acute injection of JWH 133,
CB2 receptor agonist, used in our experiments at the doses
0.05–1.0 mg/kg, but not at the dose of 2.0 mg/kg, also de-
creased locomotion of mice. An acute injection of JWH 133
(2.0 mg/kg) of its own had no statistical significant influence
on the locomotor activity of mice. However, an acute injection
of JWH 133 at the non-effective dose of 2.0 mg/kg intensified
the MK-801-provoked hyperactivity.
The first CB2 receptor ligand-related effect that should be
discussed is associated with the fact that both the CB2 agonist
(2.0 mg/kg; not a lower dose) and CB2 antagonist (2.0 mg/kg;
not a lower dose) altered MK-801 locomotor effects (similar
effects). The second interest CB2 receptor ligand effect should
focused on the fact that these cannabinoid compounds had no
effect of their own (i.e., without MK-801 injection) on loco-
motor activity.
The increase of MK-801 induced hyperactivity caused by
both CB2 antagonist and CB2 agonist obtained in our studies
seems to be very important. The same direction of action we
have is revealed in our previous studies. We have shown the
enhancement of memory and learning processes by an acute
administration of CB2 receptor agonist (JWH 133 at the doses
of 0.5; 1.0 and 2.0 mg/kg) and antagonist (AM 630 at the dose
of 1.0; 2.0 and 3.0 mg/kg) assessed in the passive avoidance
(PA) test (Kruk-Slomka et al. 2016a). Similarly, we have re-
vealed that an acute administration of both JWH 133 (0.5 and
1.0 mg/kg) and AM 630 (0.5 mg/kg) exhibited antidepressant
action in the forced swimming test (FST) (Kruk-Slomka et al.
2015). These results confirmed in our present and previous
cited experiments may be connected with pharmacokinetic
properties of used CB2 receptor ligands, especially the CB2-
selective agent, AM 630. The pharmacological properties of
AM630 are complex. It has been shown that AM 630 behaves
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Fig. 4 Effect of AM 630 onMK-
801-induced hyperactivity in
mice. Non-effective dose of AM
630 (2.0 mg/kg, ip) or vehicle
were administered 15 min prior to
vehicle or effective (0.3 mg/kg,
ip) (a) and (0.6 mg/kg; ip) (b)
dose of MK-801. After the last
injection, the mice were then
tested in actimeters; n = 8–12; the
means ± SEM; **p < 0.01;
***p < 0.001 vs. vehicle/vehicle-
treated group; &p < 0.05;
&&&p < 0.001 vs. vehicle/MK-
801(0.3 mg/kg)-treated group;
^p < 0.05; ^^p < 0.01;
^^^p < 0.001 vs. vehicle/MK-
801(0.6 mg/kg)-treated group;
Bonferroni’s test
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as inverse agonist rather than as Bsilent^ antagonist. The in-
verse efficacy at CB2 receptors but also the CB2/CB1 affinity
ratio has been indicated forAM630 (CB2/CB1 affinity = 165).
Thus, AM 630 has been found to behave as an inverse agonist
at CB2 receptors as well as an inverse agonist at CB1 recep-
tors (Bolognini et al. 2012; Ross et al. 1999).
Naturally, the administration of different doses of selective
CB2 receptor agonists/antagonists provides some information
for a neurophysiological role of CB2 receptors in the brain,
although non-selective effects at these doses cannot be ruled
out. What is of interest, it has been revealed that CB2 receptor
antagonist, SR144528, causes biphasic effects on the locomo-
tion of mice, increasing spontaneous locomotor activity in the
DBA/2 mouse at low doses (1.0–10.0 mg/kg) and decreasing
this activity at high doses (20.0 mg/kg) (Onaivi et al. 2008).
Although, Sain et al. (2009) as well as Whiteside et al. (2005)
revealed that genetic deletion of the CB2 receptor has not been
connected with any change in motor effects. On the other
hand, increasing doses of the CB2 receptor agonist, JWH-
015, decreased locomotor activity and stereotyped behavior
what was depended on the gender of animals (Onaivi et al.
2006). Similarly, typical hypolocomotion was observed after
administration of an alternative CB2 receptor agonist GW
405833 (Valenzano et al. 2005) but the injection of the selec-
tive CB2 receptor agonists HU 308 and AM 1214, at doses
provoking significant antinociceptive effects, did not affect
locomotor activity (Hanus et al. 1999; Malan et al. 2001).
Additionally, Xi et al. (2011) have revealed that intranasal
or intra-accumbens local administration of CB2 receptor ago-
nist, JWH 133, dose-dependently inhibits cocaine-enhanced
locomotion in wild-type (WT) and CB1 receptor-knockout
(CB1−/−), but not CB2−/− mice. This inhibition is mimicked
by GW 405833, another CB2 receptor agonist with a different
chemical structure, and is blocked by AM 630, a selective
CB2 receptor antagonist. Intra-accumbens administration of
JWH 133 alone dose-dependently decreases, while intra-
accumbens AM 630 elevates locomotion in WT and CB1−/−
mice, but not in CB2−/− mice.
Our results indicating that CB2 receptor ligands did not
affect locomotor activity in the dose used (2.0 mg/kg) are
consistent also with other literature data (Ishiguro et al.
2010; Kim and Li 2015; Khella et al. 2014; Onaivi 2009;
Ortega-Alvaro et al. 2011). The data indicating the role of
CB2 receptor agonist in the MK-801-induced disruptions of
PPI in mice seem to be interesting (Khella et al. 2014). In this
cited experiment, JWH 015, a CB2 receptor agonist had no
significant effect on prepulse inhibition (PPI) alone but re-
versed disruptions in PPI induced by MK-801. This effect
was attenuated by the injection of AM 630, but not by AM
251, CB1 receptor antagonist, suggesting an involvement of
CB2 receptors in these effects. Additionally, JWH 203, the
mixed CB1/CB2 receptor agonist only partially reduced
MK-801-induced PPI disruptions but neither AM 630 nor
AM 251 had any significant effect alone or on MK-801-
induced disruptions in PPI (Khella et al. 2014). In turn,
Ishiguro et al. (2010) have confirmed that AM 630 exacerbat-
edMK-801- or methamphetamine-induced disturbance of PPI
and hyperactivity in C57BL/6JJmsSlc mice. Thus, we can
suspect that the inhibition of the activity of CB2 receptor by
AM 630 at the dose of 2.0 mg/kg is not able to contribute to
the emergence of symptoms of schizophrenia. However, the
inhibition of the function of receptor CB2 in combination with
other risk factors (e.g., the impairment of glutamatergic trans-
mission by the use of NMDA receptor antagonist—MK-801)
may provoke or potentiate the symptoms of schizophrenia,
perhaps in the people predisposed to schizophrenia. Perhaps,
the possible explanation of our results is connected with the
fact that pharmacological ligands targeting CB2 receptor
(JWH 133 and AM 630) in the normal conditions (without
injection ofMK-801) and in the highest dose used (2.0mg/kg)
had no influence on the locomotor activity in mice. But in the
presence of some risk factor of schizophrenia in animals (e.g.,
administration of MK-801), CB2 expression in the brain is
changed and CB2 receptor ligands exhibit potent antipsychot-
ic (anti-hyperactivity) effects. Naturally, we can only support
these conclusions and more detailed knowledge of these ef-
fects needs further investigations.
The mechanism of action of CB2 receptor ligands in
psychosis-like responses in mice is still unclear. Although, a
number of studies have investigated the association between
cannabis and psychosis, many questions remain unanswered.
It has been known that endocannabinoid system, mainly via
CB1 receptors, is involved in pathomechanisms of schizo-
phrenia (Barzegar et al. 2015; Kruk-Slomka et al. 2016b;
Kucerova et al. 2014; Levin et al. 2012; Roser and
Haussleiter 2012), while the CB2 receptors locating outside
the CNS are involved in the processes related to the function
of the immune system (Fukuda et al. 2014; Pertwee 2010;
Wright et al. 2008). However, recent studies have provided
evidence that CB2 receptors may also be arranged outside the
cells of the immune system. Literature data suggested that
these receptors can also be found in various brain regions of
humans and many animal species (Benito et al. 2008; Zhang
et al. 2014). The studies on the biochemical and histological
level have revealed that the CB2 receptors are located in the
neuronal progenitor cells, neurons, glial chambers, and endo-
thelium. There is also evidence for the expression of CB2
receptors in areas of the brain that are particularly pertinent
to the context of schizophrenia, such as regions involved in
sensorimotor gating (Onaivi 2009; Racz et al. 2008; Zhang
et al. 2014), but the functional significance of this discovery
has not been established yet.
Following that, the functional role of central CB2 receptors
is not fully elucidated yet. Recent evidence obtained from
pharmacological (Ishiguro et al. 2010; Kim and Li 2015;
Onaivi 2009; Ortega-Alvaro et al. 2011) and genetic studies
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(Ortega-Alvaro et al. 2011) suggest that centrally expressed
CB2 receptors are involved in many processes of neuropsy-
chiatric disorders, such as behavior characteristic of schizo-
phrenia, impulsive behavior, locomotor activity, stereotyped
behaviors, anxiety-, pain-, and memory-related processes
(Khella et al. 2014; Kim and Li 2015; Kruk-Slomka et al.
2016a). Moreover, literature data (Kruk-Slomka et al. 2015;
Onaivi 2009) revealed the possible involvement of CB2 re-
ceptors in depression, which may be of importance in many
psychiatric disorders connecting with emotional imbalance,
including schizophrenia. What is more, the literature data in-
dicated that the deletion of the gene encoding CB2 receptors
may lead to neurochemical changes which can be a conse-
quence of a behavioral disorder mentioned above (Ishiguro
et al. 2010; Ortega-Alvaro et al. 2011).
We confirmed in results presented in this paper that both
stimulation and blockade of CB2 receptors is able to modulate
locomotor activity of mice that correlates with the neuropsy-
chiatric effects. It has been known that the neuropsychiatric
effects of endocannbinoid system, via CB1 and CB2 recep-
tors, are associated with the modulation of different neuro-
transmitter systems, such as dopaminergic system, glutamater-
gic system, or GABA-related system (Broome et al. 2005;
Carlsson et al. 2004). A variety of pre-clinical and clinical
studies have indicated that mainly CB1 receptors participate
in many central pathways connected with psychosis-like state
through influence on the glutamatergic transmission
(Barzegar et al. 2015; Kruk-Slomka et al. 2016b). However,
in the case of CB2 receptors, many literature data suggested an
important role of CB2 receptors, locating in the specific brain
areas, mainly on the dopaminergic neurons in the ventral teg-
mental area (VTA). Electrophysiological studies have demon-
strated that CB2 receptor activation by JWH 133 or other CB2
receptor agonists leads to inhibition of dopaminergic neuron
activation in the VTA. Therefore, these CB receptors play an
important role in the modulation of dopaminergic system and
are involved in the behaviors connecting with dopaminergic
system-related disorders, such as schizophrenia, anxiety, de-
pression, and Parkinson disease (Zhang et al. 2014).
Additionally, the endocannabinoid system via CB2 receptors
can be associated with schizophrenia-like response, due to the
fact that this type of receptors is responsible for the increase of
amount of annandamide, the main endocannabinoid occurring
in the brain. The clinical studies confirmed that the clinical
remission of schizophrenia may be connected with the signif-
icant decrease in the level of anandamide and messenger ribo-
nucleic acid (mRNA) encoding CB2 receptors (Ishiguro et al.
2010; Vigano et al. 2008). However, there are significant spe-
cies differences in CB2 receptor mRNA splicing and expres-
sion, protein sequences, and CB2 receptor ligand-related in
mice and rats (Zhang et al. 2015) indicating that the cellular
mechanisms underlying these actions are still unclear; there-
fore, the function of cannabinoid CB2 receptors in the brain
have been subject to debate. Following that, the influence of
CB2 agonists and antagonists on hyperlocomotion of mice is
controversial and inconsistent, for this reason need further
investigation.
Conclusion
The results presented in this paper, as well as the cited litera-
ture data, allow evaluating the possible relationship between
endocannbinoid system and positive symptoms of schizophre-
nia, focusing on the CB2 receptors. It can also be assumed that
modulation of the CB2 receptor function in combination with
other risk factors (e.g., disturbances in the glutamatergic trans-
mission) may lead to the onset or intensification of the symp-
toms of schizophrenia. However, further behavioral studies
would be required to conclusively establish the role of CB2
receptors in schizophrenia and would be essential in under-
standing and developing the pharmacological profile of novel
antipsychotics in the future.
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